Two-grade metabolic tumour tissue assessment using positron emission tomography in prediction of overall survival in glioblastoma patients-Reference-Cited by-同舟云学术

Two-grade metabolic tumour tissue assessment using positron emission tomography in prediction of overall survival in glioblastoma patients

Published:2021 Issue:12 Volume:78 Page:1330-1337
ISSN:0042-8450
Container-title:Vojnosanitetski pregled
language:en
Short-container-title:VOJNOSANIT PREGL

Author:

Lucic Silvija¹,Djan Igor²,Vucaj-Cirilovic Viktorija³,Radovanovic Dragana⁴^ORCID,Kozarski Dejan⁵,Sen Li⁶,Ussov Vladimir⁷,Lucic Milos³

Affiliation:

1. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Nuclear Medicine Center, Novi Sad, Serbia

2. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Clinical Center of Serbia, Neurosurgery Clinic, Department of Stereotaxic Radiosurgery, Belgrade, Serbia

3. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Diagnostic Imaging Center, Novi Sad, Serbia

4. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Oncology Institute of Vojvodina, Clinic for Oncological Surgery, Department of Anesthesiology, Intensive Therapy and Care, Novi Sad, Serbia

5. Oncology Institute of Vojvodina, Diagnostic Imaging Center, Novi Sad, Serbia

6. Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Medical Imaging Department, Shenyang, Liaoning Province, People’s Republic of China

7. Russian Academy of Sciences, National Research Polytechnic University, Scientific Research Institute of Cardiology, National Research Medical Center, Tomsk, Russia

Abstract

Background/Aim. Although considered rare, gliomas cause morbidity and mortality disproportionate to their incidence. The aim of the study was to determine whether pre and post-therapeutic metric values, derived from the FDG PET/CT maximal standardized uptake value (SU-Vmax) and calculated ratios between tumor and normal brain tissue, may provide a predictive/prognostic biomarker information in estimating overall survival of glioblastoma patients. Methods. In 26 out of 31 patients with glioblastoma treated with standard Stupp protocol after maximal safe reductive surgery, we performed a baseline 18F-FDG PET/CT examination before commencing combined and concomitant chemotherapy/radiotherapy (pre-therapy FDG PET/CT) and a second examination three months after the therapy completion (post-therapy FDG PET/CT). Two-graded SUVmax values and a calculated ratio of uptake in tumor-to-normal-tissue (T/N ratio) value, divided into two grades by the calculated cut-off value, were measured in all patients at both pre- and post-therapy FDG PET/CT studies. Data sets were statistically analyzed by the Kaplan-Meier survival test and Log-rank was calculated, with the level of confidence determined at p < 0.05. Results. Pre-therapy FDG PET/CT two-grade T/N ratio value and both pre-and post-therapy FDG PET/CT derived two-grade SUVmax values had a strong predictive impact on overall survival of glioblastoma patients. Conclusion. Based on two-grade SUVmax and T/N ratio values assessment, FDG PET/CT could provide valuable predictive survival information in glioblastoma patients and serve as a selection tool for identifying patients at higher risk from worse outcomes and shorter survival time.

Publisher

National Library of Serbia

Subject

Pharmacology (medical),General Medicine